Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of Influenza Vaccination in Athletes
NCT03654937Phase 4Completed
- Sponsor
- Saarland University
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, open-label trial of Influsplit in influenza (2 arms), sponsored by Saarland University. Primary endpoints: Immune response at 26 weeks and Rate of side effects at 2 weeks. Started Sep 2016; status: completed.
02
Drugs
Influsplit
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03654937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654937.